Phenol, 4,4'-isopropylidenedi-
RTECS #
SL6300000
CAS #
Updated
March 2019
Molecular Weight
228.31
Molecular Formula
C15H16O2
Synonyms
2,2-(4,4'-Dihydroxydiphenyl)propane
2,2-Bis(4-hydroxyphenyl)propane
2,2-Bis(p-hydroxyphenyl)propane
2,2-Bis-4'-hydroxyfenylpropan (Czech)
2,2-Di(4-hydroxyphenyl)propane
2,2-Di(4-phenylol)propane
4,4'-Bisphenol A
4,4'-Dihydroxy-2,2-diphenylpropane
4,4'-Dihydroxydiphenyl-2,2-propane
4,4'-Dihydroxydiphenyldimethylmethane
4,4'-Dihydroxydiphenylpropane
4,4'-Isopropylidendiphenol
4,4'-Isopropylidendiphenol dust
4,4'-Isopropylidenebisphenol
beta-Di-p-hydroxyphenylpropane
Bis(4-hydroxyphenyl) dimethylmethane
Bis(4-hydroxyphenyl)propane
Bisferol A (Czech)
Bisphenol
Bisphenol A
Bisphenol A (OSHA)
DIAN
Dimethyl bis(p-hydroxyphenyl)methane
Dimethylmethylene-p,p'-diphenol
Diphenylolpropane
NCI-C50635
p,p'-Dihydroxydiphenyldimethylmethane
p,p'-Dihydroxydiphenylpropane
p,p'-Isopropylidenebisphenol
p,p'-Isopropylidenediphenol
Phenol, 4,4'-dimethylmethylenedi-
Propane, 2,2-bis(p-hydroxyphenyl)-
Ucar bisphenol A
2,2-Bis(4-hydroxyphenyl)propane
2,2-Bis(p-hydroxyphenyl)propane
2,2-Bis-4'-hydroxyfenylpropan (Czech)
2,2-Di(4-hydroxyphenyl)propane
2,2-Di(4-phenylol)propane
4,4'-Bisphenol A
4,4'-Dihydroxy-2,2-diphenylpropane
4,4'-Dihydroxydiphenyl-2,2-propane
4,4'-Dihydroxydiphenyldimethylmethane
4,4'-Dihydroxydiphenylpropane
4,4'-Isopropylidendiphenol
4,4'-Isopropylidendiphenol dust
4,4'-Isopropylidenebisphenol
beta-Di-p-hydroxyphenylpropane
Bis(4-hydroxyphenyl) dimethylmethane
Bis(4-hydroxyphenyl)propane
Bisferol A (Czech)
Bisphenol
Bisphenol A
Bisphenol A (OSHA)
DIAN
Dimethyl bis(p-hydroxyphenyl)methane
Dimethylmethylene-p,p'-diphenol
Diphenylolpropane
NCI-C50635
p,p'-Dihydroxydiphenyldimethylmethane
p,p'-Dihydroxydiphenylpropane
p,p'-Isopropylidenebisphenol
p,p'-Isopropylidenediphenol
Phenol, 4,4'-dimethylmethylenedi-
Propane, 2,2-bis(p-hydroxyphenyl)-
Ucar bisphenol A
Skin and Eye Irritation and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| eye /rabbit | 250 µg/24H | severe | 85JCAE -,238,1986 |
| skin /rabbit | 10%/2D- intermittent | TPKVAL 2,50,1961 | |
| skin /rabbit | 250 mg open irritation test | mild | UCDS** 7/14/1965 |
| skin /rabbit | 500 mg/24H | mild | 85JCAE -,238,1986 |
Mutation Data and Reference
| System Test | Route/Organism/Tissue | Dose | Reference |
|---|---|---|---|
| Cytogenetic Analysis | ovary/hamster | 399 µmol/L | MUREAV 608,28,2006 |
| Cytogenetic Analysis | /hamster | 399 µmol/L | MUREAV 608,28,2006 |
| Cytogenetic Analysis | ovary/hamster | 0.5 mmol/L/3H | MUREAV 649,114,2008 |
| Cytogenetic Analysis | lung/hamster | 8.4 mg/L/20H | MUREAV 651,56,2008 |
| Cytogenetic Analysis | ovary/mouse | 3 nmol/L/12D | MUREAV 651,71,2008 |
| Cytogenetic Analysis | ovary/mouse | 10 mg/L/16H | MUREAV 651,82,2008 |
| Cytogenetic Analysis | other cell types/human | 5 mg/L | MUTAEX 17,509,2002 |
| Cytogenetic Analysis | fibroblast/hamster | 4.2 mg/L | MUTAEX 17,509,2002 |
| Cytogenetic Analysis | oral/mouse | 10 mg/kg | MUREAV 676,106,2009 |
| Cytogenetic Analysis | oral/mouse | 50 mg/kg/5D- intermittent | MUREAV 676,106,2009 |
| Cytogenetic Analysis | lymphocyte/human | 10 mg/L/22H | MUREAV 651,46,2008 |
| Cytogenetic Analysis | other cell types/human | 10 µg/L/72H | MUREAV 751,27,2013 |
| Cytogenetic Analysis | oral/rat | 60 mg/kg/6D- intermittent | MUREAV 743,83,2012 |
| DNA adduct | oral/mouse | 1600 mg/kg/8D- intermittent | MUREAV 679,28,2009 |
| DNA adduct | other cell types/cattle | 10.96 µmol/L/30M (+enzymatic activation step) | MUREAV 679,28,2009 |
| DNA adduct | intraperitoneal/rat | 200 mg/kg | EMMUEG 26,60,1995 |
| DNA adduct | oral/rat | 800 mg/kg/4D-continuous | EMMUEG 26,60,1995 |
| DNA Damage | liver/rat | 200 µmol/L | MUREAV 368,59,1996 |
| DNA Damage | other cell types/mouse | 100 mg/L/3H (-enzymatic activation step) | MUREAV 541,9,2003 |
| DNA Damage | Ascites tumor/human | 25 mg/L/2H | FCTOD7 42,1323,2004 |
| DNA Damage | oral/mouse | 100 mg/kg | TOXID9 44,456,2005 |
| DNA Damage | ovary/hamster | 0.7 mmol/L/1H | MUREAV 649,114,2008 |
| DNA Damage | oral/rat | 60 mg/kg/6D- intermittent | MUREAV 743,83,2012 |
| DNA Damage | oral/rat | 2000 mg/kg/10D- intermittent | MUREAV 752,57,2013 |
| DNA Damage | multiple/other insects | 0.5 mg/L/24H | MUREAV 758,41,2013 |
| DNA Damage | multiple/other insects | 0.5 mg/L/96H-continuous | MUREAV 758,41,2013 |
| DNA Damage | other cell types/rat | 50 µmol/L/24H | MUREAV 769,29,2014 |
| DNA Damage | other cell types/human | 40 µmol/L/1D | MUTAEX 31,43,2016 |
| DNA Damage | leukocyte/human | 0.1 mg/L/1H | FCTOD7 100,62,2017 |
| DNA Damage | liver/human | 10 nmol/L/24H | FCTOD7 105,73,2017 |
| DNA Damage | other cell types/human | 100 µmol/L | RTOPDW 55,188,2009 |
| DNA inhibition | ovary/hamster | 400 µmol/L | MUREAV 400,169,1998 |
| DNA repair | leukocyte/human | 10 mg/L/4H | FCTOD7 100,62,2017 |
| heritable translocation test | oral/mouse | 280 mg/kg/8W- intermittent | MUREAV 789-790,36,2015 |
| micronucleus test | oral/rat | 60 mg/kg/6D- intermittent | MUREAV 743,83,2012 |
| micronucleus test | lymphocyte/human | 12.3 mg/L/22H | MUREAV 651,56,2008 |
| micronucleus test | other cell types/human | 10 µg/L/72H | MUREAV 751,27,2013 |
| micronucleus test | lung/hamster | 200 µmol/L | MUREAV 390,21,1997 |
| micronucleus test | other cell types/human | 10 mg/L | MUTAEX 17,509,2002 |
| mutation in microorganisms | /Salmonella typhimurium | 0.1 µg/plate/24H (+/-enzymatic activation step) | TCMUD8 22,425,2002 |
| other mutation test systems | other cell types/human | 1 mg/L/24H | MUREAV 751,27,2013 |
| other mutation test systems | other cell types/human | 10 µg/L/72H | MUREAV 751,27,2013 |
| sister chromatid exchange | ovary/hamster | 0.4 mmol/L/3H | MUREAV 649,114,2008 |
| specific locus test | liver/mouse | 150 µmol/L/6H | EMMUEG 57,643,2016 |
Reproductive Effects Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| implant/monkey | 100 mg/kg (100-155D prior to copulation) | Reproductive: Effects on newborn: Other postnatal measures or effects | NRTXDN 35,113,2013 |
| intraperitoneal/mouse | 1200 mg/kg (6-17D pregnant) | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Behavioral | TXCYAC 296,73,2012 |
| intraperitoneal/rat | 82.5 µg/kg (12D preg-21D after birth) | Reproductive: Effects on newborn: Behavioral | TOLED5 225,479,2014 |
| intraperitoneal/rat | 1275 mg/kg (1-15D pregnant) | Reproductive: Specific developmental abnormalities: Musculoskeletal system | SWEHDO 7(Suppl 4),66,1981 |
| intraperitoneal/rat | 1275 mg/kg (1-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | APTOD9 19,A23,1980 |
| intraperitoneal/rat | 1875 mg/kg (1-15D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | APTOD9 19,A23,1980 |
| intraperitoneal/rat | 1275 mg/kg (1-15D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Central nervous system | SWEHDO 7(Suppl 4),66,1981 |
| intraperitoneal/rat | 1875 mg/kg (1-15D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Specific developmental abnormalities: Gastrointestinal system | SWEHDO 7(Suppl 4),66,1981 |
| oral/mouse | 12500 mg/kg (6-15D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Effects on embryo or fetus: Fetal death | NTIS** PB85-205102 |
| oral/mouse | 7500 mg/kg (6-15D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | NTIS** PB85-205102 |
| oral/mouse | 12500 mg/kg (6-15D pregnant) | Reproductive: Maternal effects: Uterus, cervix, vagina | NTIS** PB85-205102 |
| oral/mouse | 16800 ng/kg (11-17D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Delayed effects | AMZOAF 40,429,2000 |
| oral/rat | 10 gm/kg (6-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | NTIS** PB85-205110 |
| oral/rat | 15 gm/kg (6-15D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | NTIS** PB85-205110 |
| oral/rat | 6400 µg/kg (13-22D preg/1-6D after birth) | Reproductive: Effects on newborn: Behavioral | PBBHAU 64,687,1999 |
| oral/mouse | 14000 ng/kg (11-17D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | TIHEEC 14,239,1998 |
| oral/rat | 20 gm/kg (1-20D pregnant) | Reproductive: Effects on embryo or fetus: Fetal death Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Other effects to embryo or fetus | LIFSAK 69,2611,2001 |
| oral/rat | 2120 µg/kg (10D pre-21D after birth) | Reproductive: Effects on newborn: Behavioral | EVHPAZ 110(Suppl 3),403,2002 |
| oral/rat | 8000 µg/kg (1-14D preg/6D after birth) | Reproductive: Effects on newborn: Behavioral | EVHPAZ 110(Suppl 3),403,2002 |
| oral/rat | 1760 µg/kg (0-22D preg/21D after birth) | Reproductive: Effects on newborn: Behavioral Reproductive: Effects on newborn: Delayed effects | EVHPAZ 110(Suppl 3),409,2002 |
| oral/mouse | 50 µg/kg (14-18D pregnant) | Reproductive: Other effects on female Reproductive: Effects on newborn: Behavioral | EVHPAZ 110(Suppl 3),415,2002 |
| oral/mouse | 12500 mg/kg (6-15D pregnant) | Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | FAATDF 8,571,1987 |
| oral/mouse | 1.75 gm/kg (multigenerations) | Reproductive: Effects on newborn: Viability index (e.g., # alive at day 4 per # born alive) | NTIS** #PB86103207 |
| oral/mouse | 153 gm/kg (multigenerations) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) | NTIS** #PB86103207 |
| oral/mouse | 171.5 gm/kg (98D male) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) | NTIS** #PB86103207 |
| oral/mouse | 437 mg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Hepatobiliary system Reproductive: Specific developmental abnormalities: Urogenital system | NTIS** #PB86103207 |
| oral/rat | 0.2 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Respiratory system Reproductive: Effects on newborn: Physical | REPTED 15,505,2001 |
| oral/rat | 0.2 µg/kg (multigenerations) | Reproductive: Effects on newborn: Behavioral | REPTED 15,505,2001 |
| oral/rat | 2 µg/kg (multigenerations) | Reproductive: Effects on newborn: Physical | REPTED 15,505,2001 |
| oral/rat | 20 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | REPTED 15,505,2001 |
| oral/rat | 0.2 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Urogenital system | REPTED 15,505,2001 |
| oral/rat | 200 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Cardiovascular (circulatory) system | REPTED 15,505,2001 |
| oral/rat | 2 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Endocrine system Reproductive: Specific developmental abnormalities: Urogenital system | REPTED 15,505,2001 |
| oral/rat | 20 µg/kg (multigenerations) | Reproductive: Specific developmental abnormalities: Central nervous system | REPTED 15,505,2001 |
| oral/rat | 3.8 mg/kg (6-22D preg/21D after birth) | Nutritional and Gross Metabolic: Other changes | EVHPAZ 109,675,2001 |
| oral/rat | 45.6 mg/kg (6-22D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Endocrine system Reproductive: Effects on newborn: Delayed effects Nutritional and Gross Metabolic: Other changes | EVHPAZ 109,675,2001 |
| oral/mouse | 14 µg/kg (11-17D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Behavioral | EVHPAZ 111,175,2003 |
| oral/mouse | 560 mg/kg (8W male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | LIFSAK 72,1159,2003 |
| oral/rat | 132 mg/kg (10-22D preg/20D after birth) | Reproductive: Effects on newborn: Behavioral | ETOPFR 14,99,2003 |
| oral/rat | 800 mg/kg (10-22D preg/7D after birth) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | ETOPFR 14,99,2003 |
| oral/mouse | 640 mg/kg (0D preg-10D after birth) | Reproductive: Specific developmental abnormalities: Blood and lymphatic systems (including spleen and marrow) | TXAPA9 197,233,2004 |
| oral/rat | 20 mg/kg (6D preg -4D after birth) | Reproductive: Specific developmental abnormalities: Endocrine system | TOXID9 44,202,2005 |
| oral/rat | 1.6 mg/kg (6-21D pregnant) | Reproductive: Effects on newborn: Other postnatal measures or effects | TOXID9 78,74,2004 |
| oral/rat | 32 µg/kg (6-21D pregnant) | Reproductive: Effects on newborn: Germ cell effects (in offspring) | TOXID9 78,118,2004 |
| oral/rat | 2700 mg/kg (15-22D preg/10D after birth) | Reproductive: Other effects on female Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | ARTODN 78,97,2004 |
| oral/rat | 82.5 mg/kg (multigeneration) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | TOXID9 60,297,2001 |
| oral/rat | 825 mg/kg (multigeneration) | Reproductive: Specific developmental abnormalities: Hepatobiliary system Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) | TOXID9 60,297,2001 |
| oral/mouse | 10500 mg/kg (21D prior to copulation/21D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) Reproductive: Effects on newborn: Live birth index (Litter size (e.g., # fetuses per litter; measured after birth) | TOXID9 66,372,2002 |
| oral/rat | 460 mg/kg (1-23D pregnant) | Reproductive: Effects on newborn: Biochemical and metabolic | HETOEA 25,369,2006 |
| oral/rat | 6300 mg/kg (multigeneration) | Reproductive: Other effects on male Reproductive: Maternal effects: Ovaries, fallopian tubes Reproductive: Other effects on female | HPV060 -,-,2006 |
| oral/rat | 50 mg/kg (multigeneration) | Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | REPTED 28,196,2009 |
| oral/rat | 39 mg/kg (3D preg-20D after birth) | Reproductive: Effects on newborn: Behavioral | BDERB* 83,157,2008 |
| oral/mouse | 0.08 mg/kg (11-18D pregnant) | Reproductive: Effects on newborn: Behavioral | BDERB* 83,157,2008 |
| oral/rat | 1.6 mg/kg (6-21D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) | BDERB* 83,157,2008 |
| oral/rat | 1290 µg/kg (1-22D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Other developmental abnormalities | NERADN 45,345,2003 |
| oral/rat | 12900 µg/kg (1-22D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Urogenital system Reproductive: Other developmental abnormalities | NERADN 45,345,2003 |
| oral/mouse | 5 mg/kg (multigeneration) | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Other postnatal measures or effects Reproductive: Effects on newborn: Delayed effects | TOLED5 189,40,2009 |
| oral/rat | 1720 µg/kg (0D preg-21D after birth) | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Delayed effects | TOLED5 228,85,2014 |
| oral/mouse | 43 mg/kg (1D preg-21 after birth) | Reproductive: Effects on newborn: Other postnatal measures or effects | FCTOD7 83,17,2015 |
| oral/mouse | 5 µg/kg (11-21D pregnant) | Reproductive: Effects on newborn: Other postnatal measures or effects Reproductive: Effects on newborn: Delayed effects | TXAPA9 284,354,2015 |
| oral/domestic animal | 3 mg/kg (30-90D pregnant) | Reproductive: Effects on newborn: Other postnatal measures or effects | TXAPA9 278,119,2014 |
| oral/rat | 37.5 µg/kg (multigeneration) | Reproductive: Effects on newborn: Other postnatal measures or effects | NETEEC 34,331,2012 |
| oral/rat | 88 µg/kg (multigeneration) | Reproductive: Effects on newborn: Biochemical and metabolic | NETEEC 42,17,2014 |
| oral/rat | 215 µg/kg (multigeneration) | Reproductive: Other developmental abnormalities Reproductive: Effects on newborn: Behavioral | NETEEC 41,16,2014 |
| oral/monkey | 26000 µg/kg (100-165D prior to copulation) | Reproductive: Effects on newborn: Other postnatal measures or effects | NRTXDN 35,113,2013 |
| oral/rat | 210 µg/kg (12D pre-10D after birth) | Reproductive: Effects on newborn: Other postnatal measures or effects | NRTXDN 36,55,2013 |
| oral/rat | 39.6 µg/kg (12-23D preg/21D after birth) | Reproductive: Effects on newborn: Germ cell effects (in offspring) Reproductive: Effects on newborn: Other postnatal measures or effects Reproductive: Effects on newborn: Delayed effects | LIFSAK 85,742,2009 |
| oral/mouse | 320.4 mg/kg (7-21D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Endocrine system | EMMUEG 49,368,2008 |
| oral/rat | 0.807 mg/kg (11D preg-21D after birth) | Reproductive: Other developmental abnormalities | NETEEC 33,458,2011 |
| oral/mouse | 80 mg/kg (13-16D pregnant) | Reproductive: Other effects on female | TXAPA9 269,163,2013 |
| oral/mouse | 10.5 µg/kg (11-21D pregnant) | Reproductive: Effects on newborn: Germ cell effects (in offspring) Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Delayed effects | TXAPA9 276,157,2014 |
| oral/rat | 0.6 mg/kg (9-20D pregnant) | Reproductive: Effects on newborn: Behavioral Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Other postnatal measures or effects | TXCYAC 322,51,2014 |
| oral/mouse | 260 µg/kg (6-18D pregnant) | Reproductive: Effects on newborn: Physical Reproductive: Specific developmental abnormalities: Central nervous system | TXCYAC 323,51,2014 |
| oral/mouse | 2600 µg/kg (6-18D pregnant) | Reproductive: Effects on newborn: Behavioral | TXCYAC 323,51,2014 |
| oral/rat | 300 µg/kg (10-21D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Specific developmental abnormalities: Urogenital system | FCTOD7 84,64,2015 |
| oral/rat | 400 µg/kg (1-20D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) Reproductive: Specific developmental abnormalities: Endocrine system | FCTOD7 95,168,2016 |
| oral/rat | 300 mg/kg (10-21D pregnant) | Reproductive: Specific developmental abnormalities: Skin and skin appendages | TXAPA9 303,101,2016 |
| oral/rat | 1720 µg/kg (1D preg-21D after birth) | Reproductive: Specific developmental abnormalities: Endocrine system Reproductive: Specific developmental abnormalities: Urogenital system | TOLED5 238,30,2015 |
| oral/mouse | 1800 µg/kg (7D preg/21D after birth) | Reproductive: Effects on newborn: Behavioral | TXCYAC 378,107,2017 |
| oral/mouse | 53.2 mg/kg (1-20D preg/245D after birth) | Reproductive: Effects on embryo or fetus: Maternal- fetal exchange | TOXRE* 2,99,2015 |
| oral/rat | 2100 mg/kg (0-21D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Hepatobiliary system Reproductive: Specific developmental abnormalities: Endocrine system Reproductive: Specific developmental abnormalities: Urogenital system | TOXRE* 3,685,2016 |
| oral/rat | 425 µg/kg (6D-22D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system | NRTXDN 65,207,2018 |
| oral/mouse | 1200 µg/kg (8-13D pregnant) | Reproductive: Effects on embryo or fetus: Cytological changes (including somatic cell genetic material) Reproductive: Other effects to embryo or fetus | TXCYAC 295,31,2012 |
| subcutaneous/mouse | 1600 µg/kg (6-21D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system | TOLED5 245,59,2016 |
| subcutaneous/mouse | 2100 µg/kg (21D after birth) | Reproductive: Specific developmental abnormalities: Central nervous system | TOLED5 245,59,2016 |
| subcutaneous/mouse | 3700 µg/kg (6-21D preg/21D after birth) | Reproductive: Specific developmental abnormalities: Central nervous system | TOLED5 245,59,2016 |
| subcutaneous/domestic animal | 300 mg/kg (30-90D pregnant) | Reproductive: Specific developmental abnormalities: Central nervous system Reproductive: Specific developmental abnormalities: Endocrine system | TXAPA9 247,98,2010 |
| subcutaneous/monkey | 1120 µg/kg (20-132D pregnant) | Reproductive: Effects on newborn: Behavioral Reproductive: Effects on newborn: Delayed effects | NETEEC 44,46,2014 |
| subcutaneous/mouse | 7.5 µg/kg (8-21D preg/1-16D after birth) | Reproductive: Specific developmental abnormalities: Skin and skin appendages | REPTED 26,210,2008 |
| subcutaneous/rat | 2400 mg/kg (6W male) | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands | TOLED5 194,16,2010 |
| subcutaneous/mouse | 800 mg/kg (2-5D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | REPTED 26,94,2008 |
| subcutaneous/mouse | 300 mg/kg (1D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | REPTED 26,94,2008 |
| subcutaneous/mouse | 200 mg/kg (2D pregnant) | Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) | REPTED 26,94,2008 |
| subcutaneous/rat | 4000 mg/kg (11-20D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TERPA* -,318,2005 |
| subcutaneous/mouse | 540 mg/kg (1-4D pregnant) | Reproductive: Effects on fertility: Litter size (e.g., # fetuses per litter; measured before birth) | REPTED 23,138,2007 |
| subcutaneous/mouse | 1620 mg/kg (1-4D pregnant) | Reproductive: Maternal effects: Parturition Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | REPTED 23,138,2007 |
| subcutaneous/mouse | 11014 mg/kg (1-4D pregnant) | Reproductive: Effects on fertility: Abortion | REPTED 23,138,2007 |
| subcutaneous/rat | 50 mg/kg (11-20D pregnant) | Reproductive: Other effects to embryo or fetus | TOXID9 66,296,2002 |
| subcutaneous/mouse | 90 mg/kg (10-18D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | REPTED 16,107,2002 |
| subcutaneous/mouse | 14 µg/kg (11-17D pregnant) | Reproductive: Effects on newborn: Growth statistics (e.g., reduced weight gain) Reproductive: Effects on newborn: Physical | REPTED 16,117,2002 |
| subcutaneous/mouse | 140 µg/kg (11-17D pregnant) | Reproductive: Effects on newborn: Physical | REPTED 16,117,2002 |
| subcutaneous/rat | 400 µg/kg (8-23D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | BIREBV 65,1271,2001 |
| subcutaneous/mouse | 900 mg/kg (11-19D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | CGANE7 39,193,1999 |
| unreported route/rat | 350 mg/kg (9-15D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | VCVGK* -,234,1994 |
| unreported route/rat | 1.6 mg/kg (6-21D pregnant) | Reproductive: Effects on newborn: Biochemical and metabolic Reproductive: Effects on newborn: Other postnatal measures or effects Reproductive: Effects on newborn: Delayed effects | TOXID9 60,387,2001 |
| unreported route/rat | 4000 mg/kg (11-20D pregnant) | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | TOXID9 -,143,2009 |
| unreported route/rat | 800 mg/kg (6-21D pregnant) | Reproductive: Specific developmental abnormalities: Urogenital system | NSAPCC 369(Suppl 1),R112,2004 |
Tumorigenic Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| oral/mouse | lowest published toxic dose: 86520 mg/kg/103W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Blood: Leukemia Blood: Lymphoma including Hodgkin's disease | NTIS** PB82-184060 |
| oral/rat | lowest published toxic dose: 43260 mg/kg/103W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Blood: Leukemia Reproductive: Tumorigenic effects: Testicular tumors | NTIS** PB82-184060 |
| oral/rat | lowest published toxic dose: 36050 mg/kg/103W- continuous | Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Blood: Leukemia | NTIS** PB82-184060 |
Acute Toxicity Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| In Vitro/embryo | Inhibitor Concentration Low: 125 µmol/L/10M | Endocrine: Other changes | TIVIEQ 40,234,2017 |
| In Vitro/embryo | Inhibitor Concentration Low: 250 µmol/L/10M | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 40,234,2017 |
| In Vitro/Human, colon tumor | Inhibitor Concentration Low: 5 µmol/L/24H | In Vitro Toxicity Studies: Other assays | FCTOD7 111,125,2018 |
| In Vitro/Human, colon tumor | Inhibitor Concentration (50 percent kill): 34.85 mg/L/48H | In Vitro Toxicity Studies: Cell growth: Colony formation | FCTOD7 83,268,2015 |
| In Vitro/Human, embryonic cells | Inhibitor Concentration (50 percent kill): 138 µmol/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 38,41,2017 |
| In Vitro/Human, embryonic cells | Inhibitor Concentration (50 percent kill): 218 µmol/L/24H | In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM) | TIVIEQ 38,41,2017 |
| In Vitro/Human, embryonic cells | Inhibitor Concentration (50 percent kill): 71 µmol/L/24H | Endocrine: Other changes | TIVIEQ 38,41,2017 |
| In Vitro/Human, embryonic cells | Inhibitor Concentration Low: 50 µmol/L/15M | In Vitro Toxicity Studies: Other assays | TIVIEQ 38,41,2017 |
| In Vitro/Human, embryonic cells | Inhibitor Concentration Low: 1 nmol/L/10D | In Vitro Toxicity Studies: Cell differentiation | TOLED5 218,187,2013 |
| In Vitro/Human, endocrine tumor | Inhibitor Concentration (50 percent kill): 3 µmol/L/24H | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | TXAPA9 268,309,2013 |
| In Vitro/Human, endocrine tumor | Inhibitor Concentration Low: 25 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,107,2012 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 0.5 mg/L/4H | In Vitro Toxicity Studies: Other assays | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 0.1 mg/L/24H | In Vitro Toxicity Studies: Other assays | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 5 mg/L/4H | Biochemical: Metabolism (intermediary): Effect on Na-K pump | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 0.5 mg/L/24H | Biochemical: Metabolism (intermediary): Effect on Na-K pump | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 25 mg/L/4H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 5 mg/L/24H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase | FCTOD7 110,351,2017 |
| In Vitro/Human, erythrocytes | Inhibitor Concentration Low: 100 mg/L/4H | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase | FCTOD7 110,351,2017 |
| In Vitro/Human, HeLa cell | Inhibitor Concentration (50 percent kill): 6.98 mg/L/48H | In Vitro Toxicity Studies: Cell growth: Colony formation | FCTOD7 83,268,2015 |
| In Vitro/Human, kidney | Inhibitor Concentration (20 percent kill): 77.62 µmol/L/2H | In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. | TIVIEQ 40,66,2017 |
| In Vitro/Human, kidney | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 238,43,2015 |
| In Vitro/Human, kidney | Inhibitor Concentration (20 percent kill): 35.48 µmol/L/2H | Endocrine: Other changes | TIVIEQ 40,66,2017 |
| In Vitro/Human, liver | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 238,43,2015 |
| In Vitro/Human, liver | Inhibitor Concentration Low: 0.6 µmol/L/48H | In Vitro Toxicity Studies: Other assays | FCTOD7 111,125,2018 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 10 nmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 105,73,2017 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 10 nmol/L/6H | In Vitro Toxicity Studies: Other assays Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | FCTOD7 105,73,2017 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 1 nmol/L/5D | In Vitro Toxicity Studies: Other assays | TOLED5 272,75,2017 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 1000 nmol/L/5D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 272,75,2017 |
| In Vitro/Human, liver tumor | Inhibitor Concentration (50 percent kill): 279 µmol/L | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay | TOLED5 259,87,2016 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.001 nmol/L/4D | Biochemical: Metabolism (intermediary): Lipids including transport | TXAPA9 280,224,2014 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 0.001 nmol/L/48H | In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TIVIEQ 26,709,2012 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 1 nmol/L/24H | In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TIVIEQ 26,709,2012 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 10 µmol/L/72H | In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | TIVIEQ 26,709,2012 |
| In Vitro/Human, liver tumor | Inhibitor Concentration Low: 100 µmol/L/72H | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay | FCTOD7 70,9,2014 |
| In Vitro/Human, lung | Inhibitor Concentration (50 percent kill): 10.84 mg/L/48H | In Vitro Toxicity Studies: Cell growth: Colony formation | FCTOD7 83,268,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 220 µmol/L/4H | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay | TIVIEQ 29,1464,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration (50 percent kill): 549.6 µmol/L/4H | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay | TIVIEQ 29,1464,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 0.088 µmol/L/4H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,1464,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 0.44 µmol/L/1H | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,1464,2015 |
| In Vitro/Human, lymphocyte | Inhibitor Concentration Low: 10000 nmol/L/6H | Immunological Including Allergic: Increase in cellular immune response | FCTOD7 110,262,2017 |
| In Vitro/Human, melanoma | Inhibitor Concentration Low: 50 µmol/L/2H | Biochemical: Metabolism (intermediary): Effect on inflammation or mediation of inflammation | FCTOD7 50,2109,2012 |
| In Vitro/Human, monocyte | Inhibitor Concentration Low: 200 nmol/L/6H | Immunological Including Allergic: Decrease in cellular immune response | FCTOD7 110,262,2017 |
| In Vitro/Human, neuroblastoma | Inhibitor Concentration Low: 31.25 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 44,313,2017 |
| In Vitro/ilb | Inhibitor Concentration Low: 25 µmol/L/2H | In Vitro Toxicity Studies: Other assays | TOLED5 238,43,2015 |
| In Vitro/ilb | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 111,125,2018 |
| In Vitro/ilb | Inhibitor Concentration Low: 100 nmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 111,125,2018 |
| In Vitro/ilb | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays | TOLED5 238,43,2015 |
| In Vitro/jkb | Inhibitor Concentration Low: 4.4 µmol/L/48H | In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Other assays | TIVIEQ 29,2009,2015 |
| In Vitro/jna | Inhibitor Concentration Low: 10 mg/L/24H | Endocrine: Other changes | TIVIEQ 40,297,2017 |
| In Vitro/jpc | Inhibitor Concentration Low: 20 mg/L/24H | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay | FCTOD7 84,79,2015 |
| In Vitro/jpc | Inhibitor Concentration Low: 5 mg/L/24H | In Vitro Toxicity Studies: Apoptosis in vitro | FCTOD7 84,79,2015 |
| In Vitro/jpc | Inhibitor Concentration Low: 0.1 mg/L/12H | Biochemical: Metabolism (intermediary): Effect on mitochondrial function | FCTOD7 84,79,2015 |
| In Vitro/jpc | Inhibitor Concentration Low: 10 µmol/L/18H | In Vitro Toxicity Studies: Other assays | TXCYAC 303,17,2013 |
| In Vitro/jqa | Inhibitor Concentration Low: 5 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 210,95,2012 |
| In Vitro/jrc | Inhibitor Concentration Low: 0.1 nmol/L | Endocrine: Estrogenic | FCTOD7 50,3100,2012 |
| In Vitro/jrc | Inhibitor Concentration Low: 4 nmol/L/3W | In Vitro Toxicity Studies: Other assays | TXAPA9 248,111,2010 |
| In Vitro/jrc | Inhibitor Concentration Low: 1000 nmol/L/30M | In Vitro Toxicity Studies: Other assays | TXAPA9 248,111,2010 |
| In Vitro/jrd | Inhibitor Concentration Low: 1 µmol/L/1D | In Vitro Toxicity Studies: Cell counting | TOLED5 199,261,2010 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 nmol/L/72H | In Vitro Toxicity Studies: Cell counting | TOLED5 199,261,2010 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 nmol/L/72H | In Vitro Toxicity Studies: Other assays | TOLED5 199,261,2010 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 µmol/L/6H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1467,2013 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 206,158,2011 |
| In Vitro/jrd | Inhibitor Concentration (50 percent kill): 0.47 µmol/L/6D | Endocrine: Estrogenic | TXAPA9 272,127,2013 |
| In Vitro/jrd | Inhibitor Concentration (50 percent kill): 3.24 mg/L/48H | In Vitro Toxicity Studies: Cell growth: Colony formation | FCTOD7 83,268,2015 |
| In Vitro/jrd | Inhibitor Concentration Low: 1 nmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 30,521,2015 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 nmol/L/24H | Endocrine: Estrogenic | TIVIEQ 30,521,2015 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 nmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. Endocrine: Estrogenic | TIVIEQ 30,521,2015 |
| In Vitro/jrd | Inhibitor Concentration (50 percent kill): 46 µg/L/6D | Endocrine: Estrogenic | FCTOD7 108,30,2017 |
| In Vitro/jrd | Inhibitor Concentration Low: 0.1 µg/L/6D | Endocrine: Estrogenic | FCTOD7 108,30,2017 |
| In Vitro/jrd | Inhibitor Concentration Low: 10 mg/L/6D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 108,30,2017 |
| In Vitro/jrd | Inhibitor Concentration Low: 100 µg/L/24H | Endocrine: Estrogenic | FCTOD7 108,30,2017 |
| In Vitro/jrd | Inhibitor Concentration Low: 0.1 µmol/L/8D | Endocrine: Estrogenic | FCTOD7 109,284,2017 |
| In Vitro/jrd | Inhibitor Concentration Low: 1 µmol/L/24H | In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. | FCTOD7 109,284,2017 |
| In Vitro/jtd | Inhibitor Concentration Low: 50 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 210,95,2012 |
| In Vitro/jte | Inhibitor Concentration Low: 10 µmol/L/48H | In Vitro Toxicity Studies: Other assays | TXCYAC 270,137,2010 |
| In Vitro/jtf | Inhibitor Concentration Low: 1 nmol/L/72H | In Vitro Toxicity Studies: Cell proliferation: DNA incorporation, mitotic index etc. | TOLED5 202,30,2011 |
| In Vitro/jtf | Inhibitor Concentration (50 percent kill): 0.2 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 206,152,2011 |
| In Vitro/jtf | Inhibitor Concentration Low: 8 µg/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 210,332,2012 |
| In Vitro/jtf | Inhibitor Concentration Low: 0.01 µmol/L/1D | In Vitro Toxicity Studies: Other assays | TXCYAC 304,21,2013 |
| In Vitro/jtf | Inhibitor Concentration Low: 0.123 µmol/L/24H | Endocrine: Estrogenic | TOLED5 206,152,2011 |
| In Vitro/jtf | Inhibitor Concentration (50 percent kill): 0.28 µmol/L/20H | Endocrine: Estrogenic | FCTOD7 95,121,2016 |
| In Vitro/jtf | Inhibitor Concentration Low: 1 µmol/L/48H | Endocrine: Estrogenic | PYTOEY 22,993,2015 |
| In Vitro/jtf | Inhibitor Concentration Low: 1 nmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 269,15,2017 |
| In Vitro/jtg | Inhibitor Concentration Low: 2.8 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 34,1,2016 |
| In Vitro/jtg | Inhibitor Concentration Low: 20 µmol/L/6H | In Vitro Toxicity Studies: Cell counting In Vitro Toxicity Studies: Other assays | TIVIEQ 34,1,2016 |
| In Vitro/jvx | Inhibitor Concentration Low: 10 nmol/L/90D | In Vitro Toxicity Studies: Other assays | TIVIEQ 29,1060,2015 |
| In Vitro/jvx | Inhibitor Concentration Low: 5 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,107,2012 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration Low: 1 µmol/L/8D | In Vitro Toxicity Studies: Cell differentiation Biochemical: Metabolism (intermediary): Lipids including transport | TIVIEQ 32,297,2016 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration Low: 100 µmol/L/10D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXAPA9 280,224,2014 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration Low: 1 nmol/L/10D | Biochemical: Metabolism (intermediary): Lipids including transport | TXAPA9 280,224,2014 |
| In Vitro/Mouse, fibroblast | Inhibitor Concentration Low: 1 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TOLED5 250-251,1,2016 |
| In Vitro/Mouse, leukemia cells | Inhibitor Concentration (50 percent kill): 28.923 mg/L/10D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | FCTOD7 60,497,2013 |
| In Vitro/Mouse, leukemia cells | Inhibitor Concentration (50 percent kill): 7.493 mg/L/10D | In Vitro Toxicity Studies: Other assays | FCTOD7 60,497,2013 |
| In Vitro/Mouse, macrophage | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 112,86,2018 |
| In Vitro/Mouse, neuroblastom | Inhibitor Concentration Low: 10 µmol/L/48H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1634,2013 |
| In Vitro/mtb | Inhibitor Concentration Low: 5 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 27,2249,2013 |
| In Vitro/mtb | Inhibitor Concentration Low: 0.04 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 27,2249,2013 |
| In Vitro/mtb | Inhibitor Concentration Low: 1 µmol/L/2D | In Vitro Toxicity Studies: Cell differentiation | TIVIEQ 27,2249,2013 |
| In Vitro/mtb | Inhibitor Concentration Low: 0.04 µmol/L/4D | In Vitro Toxicity Studies: Cell differentiation | TIVIEQ 27,2249,2013 |
| In Vitro/mtd | Inhibitor Concentration Low: 10 mg/mL/24H | Endocrine: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | TXAPA9 271,249,2013 |
| In Vitro/mtd | Inhibitor Concentration Low: 0.1 µmol/L/5D | In Vitro Toxicity Studies: Other assays | TIVIEQ 28,1424,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 2 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TXCYAC 324,27,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 20 µmol/L/24H | In Vitro Toxicity Studies: Apoptosis in vitro | TXCYAC 324,27,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 2 µmol/L/1M | Nutritional and Gross Metabolic: Changes in: Ca | TXCYAC 324,27,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 0.2 µmol/L/48H | Biochemical: Metabolism (intermediary): Effect on mitochondrial function | TXCYAC 324,27,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 0.02 µmol/L/48H | In Vitro Toxicity Studies: Apoptosis in vitro | TXCYAC 324,27,2014 |
| In Vitro/mtg | Inhibitor Concentration (50 percent kill): 50 µmol/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 226,81,2014 |
| In Vitro/mtg | Inhibitor Concentration (50 percent kill): 92 µmol/L/72H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TOLED5 226,81,2014 |
| In Vitro/mtg | Inhibitor Concentration Low: 10 µmol/L/72H | In Vitro Toxicity Studies: Cell counting | TXCYAC 387,10,2017 |
| In Vitro/mtj | Inhibitor Concentration Low: 20 µmol/L/24H | In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay In Vitro Toxicity Studies: Apoptosis in vitro | TXAPA9 314,98,2017 |
| In Vitro/mzx | Inhibitor Concentration Low: 50 µmol/L/8D | In Vitro Toxicity Studies: Cell differentiation | TIVIEQ 27,1634,2013 |
| In Vitro/mzx | Inhibitor Concentration Low: 80 µmol/L/8D | In Vitro Toxicity Studies: Cell differentiation In Vitro Toxicity Studies: Other assays | TIVIEQ 27,1634,2013 |
| In Vitro/nta | Inhibitor Concentration Low: 0.01 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TXCYAC 304,21,2013 |
| In Vitro/paa | Inhibitor Concentration Low: 0.1 mmol/L/5D | In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc. | FCTOD7 52,76,2013 |
| In Vitro/paa | Inhibitor Concentration Low: 0.1 mmol/L/5D | In Vitro Toxicity Studies: Cell differentiation | FCTOD7 52,76,2013 |
| In Vitro/paa | Inhibitor Concentration Low: 0.1 mmol/L/5D | In Vitro Toxicity Studies: Apoptosis in vitro | FCTOD7 52,76,2013 |
| In Vitro/paa | Inhibitor Concentration Low: 0.1 mmol/L/5D | In Vitro Toxicity Studies: Other assays | FCTOD7 52,76,2013 |
| In Vitro/pax | Inhibitor Concentration Low: 100 nmol/L/7D | In Vitro Toxicity Studies: Other assays | TXCYAC 272,52,2010 |
| In Vitro/pax | Inhibitor Concentration Low: 10 nmol/L/30M | In Vitro Toxicity Studies: Other assays | TXAPA9 249,188,2010 |
| In Vitro/ppf | Inhibitor Concentration Low: 100 µmol/L | In Vitro Toxicity Studies: Other assays | FCTOD7 112,86,2018 |
| In Vitro/Rat, endocrine cell (tissues) | Inhibitor Concentration Low: 1 nmol/L/1D | In Vitro Toxicity Studies: Other assays | TXCYAC 304,21,2013 |
| In Vitro/Rat, endocrine cell (tissues) | Inhibitor Concentration Low: 100 µmol/L/24H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. Endocrine: Other changes | TIVIEQ 32,310,2016 |
| In Vitro/Rat, endocrine cell (tissues) | Inhibitor Concentration (50 percent kill): 91.7 µmol/L/1H | Biochemical: Metabolism (intermediary): Effect on active transport | TIVIEQ 32,310,2016 |
| In Vitro/Rat, endocrine cell (tissues) | Inhibitor Concentration Low: 10 µmol/L/1H | Biochemical: Metabolism (intermediary): Effect on active transport | TIVIEQ 32,310,2016 |
| In Vitro/Rat, endocrine cell (tissues) | Inhibitor Concentration Low: 30 µmol/L/48H | Endocrine: Other changes | TIVIEQ 32,310,2016 |
| In Vitro/Rat, endocrine tumor | Inhibitor Concentration Low: 100 mg/L/48H | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. | TIVIEQ 40,297,2017 |
| In Vitro/Rat, endocrine tumor | Inhibitor Concentration Low: 10 mg/L/48H | Endocrine: Other changes | TIVIEQ 40,297,2017 |
| In Vitro/Rat, liver tumor | Inhibitor Concentration (50 percent kill): 8.94 mg/L/48H | In Vitro Toxicity Studies: Cell growth: Colony formation | FCTOD7 83,268,2015 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 100 µmol/L/30M | In Vitro Toxicity Studies: Other assays | TOLED5 215,126,2012 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 10 µmol/L/24H | Endocrine: Androgenic | TOLED5 207,137,2011 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 10 nmol/L/18H | In Vitro Toxicity Studies: Other assays | TOLED5 225,479,2014 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 10 µmol/L/3H | In Vitro Toxicity Studies: Other assays | TOLED5 207,137,2011 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 10 µmol/L/24H | In Vitro Toxicity Studies: Other assays | TIVIEQ 26,107,2012 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 37.5 µmol/L/16D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. Endocrine: Other changes Biochemical: Metabolism (intermediary): Glycolytic | FCTOD7 106,487,2017 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 37.5 µmol/L/24D | In Vitro Toxicity Studies: Other assays | FCTOD7 106,487,2017 |
| In Vitro/Rat, testis | Inhibitor Concentration Low: 18.75 µmol/L/24D | In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. Biochemical: Metabolism (intermediary): Glycolytic | FCTOD7 106,487,2017 |
| inhalation/human | lowest published toxic concentration: 20 mg/m3/1H | Behavioral: Headache Gastrointestinal: Nausea or vomiting | VCVGK* -,234,1994 |
| inhalation/mouse | lowest published toxic concentration: 500 mg/m3 | Behavioral: Somnolence (general depressed activity) Behavioral: Ataxia | VCVGK* -,234,1994 |
| inhalation/mouse | Lethal concentration: >1700 mg/m3/2H | Behavioral: Somnolence (general depressed activity) Behavioral: Ataxia Lung, Thorax, or Respiration: Dyspnea | TPKVAL 2,50,1961 |
| inhalation/mouse | lowest published toxic concentration: 500 mg/m3/2H | Brain and Coverings: Changes in circulation Behavioral: Somnolence (general depressed activity) Cardiac: Cardiomyopathy including infarction | TPKVAL 2,50,1961 |
| inhalation/mouse | lowest published toxic concentration: 500 mg/m3/2H | Gastrointestinal: Other changes Liver: Other changes Kidney, Ureter, and Bladder: Changes in blood vessels or in circulation of kidney | TPKVAL 7,76,1965 |
| inhalation/rat | lethal concentration (50 percent kill): >170 mg/m3/6H | HPV060 -,-,2006 | |
| inhalation/rat | lethal concentration (50 percent kill): >170 mg/m3 | BDERB* 83,157,2008 | |
| intracerebral/rat | lowest published toxic dose: 100 µg/kg | Behavioral: Change in motor activity (specific assay) | TOLED5 206,300,2011 |
| intraperitoneal/mouse | lowest published toxic dose: 100 mg/kg | Liver: Other changes | TOLED5 177,20,2008 |
| intraperitoneal/mouse | lethal dose (50 percent kill): 150 mg/kg | BDERB* 83,157,2008 | |
| intraperitoneal/rat | lowest published toxic dose: 37.5 mg/kg | Endocrine: Estrogenic Reproductive: Maternal effects: Uterus, cervix, vagina Biochemical: Metabolism (intermediary): Other | EVHPAZ 108,243,2000 |
| intraperitoneal/rat | lowest published toxic dose: 150 mg/kg | Endocrine: Estrogenic | EVHPAZ 108,243,2000 |
| intraperitoneal/rat | lethal dose (50 percent kill): 200 mg/kg | FCTOD7 41,1035,2003 | |
| ocular/rabbit | lowest published toxic dose: 100 pph | Eye: Conjunctiva irritation | TPKVAL 7,76,1965 |
| ocular/rabbit | lowest published toxic dose: 100 pph | Eye: Conjunctiva irritation Eye: Corneal damage | TPKVAL 2,50,1961 |
| oral/guinea pig | lethal dose (50 percent kill): 4 gm/kg | Autonomic Nervous System: Other (direct) parasympathomimetic Behavioral: Convulsions or effect on seizure threshold Behavioral: Ataxia | GISAAA 33(7),25,1968 |
| oral/guinea pig | lethal dose (50 percent kill): 4000 mg/kg | BDERB* 83,157,2008 | |
| oral/human | lowest published toxic dose: 357.1 ng/kg | Kidney, Ureter, and Bladder: Other changes in urine composition | TXAPA9 197,190,2004 |
| oral/mammal (species unspecified) | lethal dose (50 percent kill): 6500 mg/kg | 34ZIAG -,135,1969 | |
| oral/mouse | lowest published toxic dose: 500 mg/kg | Blood: Changes in bone marrow not included in above | TOXID9 1,102,2001 |
| oral/mouse | lowest published toxic dose: 1000 mg/kg | Behavioral: Sleep Skin and Appendages: Other: Hair | TOXID9 1,102,2001 |
| oral/mouse | lethal dose (50 percent kill): 2500 mg/kg | Lung, Thorax, or Respiration: Dyspnea Lung, Thorax, or Respiration: Other changes | TPKVAL 7,76,1965 |
| oral/mouse | lowest published lethal dose: 1000 mg/kg | Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance Gastrointestinal: Hypermotility, diarrhea | TPKVAL 7,76,1965 |
| oral/mouse | lethal dose (50 percent kill): 2400 mg/kg | Autonomic Nervous System: Other (direct) parasympathomimetic Behavioral: Convulsions or effect on seizure threshold Behavioral: Ataxia | GISAAA 33(7),25,1968 |
| oral/mouse | lethal dose (20 percent kill): 1500 mg/kg | Peripheral Nerve and Sensation: Recording from peripheral motor nerve Behavioral: Somnolence (general depressed activity) Lung, Thorax, or Respiration: Respiratory depression | TPKVAL 2,50,1961 |
| oral/mouse | lethal dose (50 percent kill): 2500 mg/kg | Brain and Coverings: Changes in circulation Liver: Fatty liver degeneration Liver: Other changes | TPKVAL 2,50,1961 |
| oral/mouse | lowest published toxic dose: 1000 mg/kg | Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, and Bladder: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TPKVAL 2,50,1961 |
| oral/mouse | lethal dose (50 percent kill): 2400 mg/kg | BDERB* 83,157,2008 | |
| oral/mouse | lowest published toxic dose: 0.32 mg/kg | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TXCYAC 290,187,2011 |
| oral/mouse | lowest published toxic dose: 3.2 mg/kg | Behavioral: Change in motor activity (specific assay) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TXCYAC 290,187,2011 |
| oral/mouse | lowest published toxic dose: 3.2 mg/kg | Biochemical: Metabolism (intermediary): Other proteins | NRTXDN 33,1390,2012 |
| oral/rabbit | lethal dose (50 percent kill): 2230 mg/kg | BDERB* 83,157,2008 | |
| oral/rat | lowest published lethal dose: 2500 mg/kg | Lung, Thorax, or Respiration: Dyspnea Lung, Thorax, or Respiration: Cyanosis | TPKVAL 2,50,1961 |
| oral/rat | lethal dose (50 percent kill): 4240 mg/kg | Kidney, Ureter, and Bladder: Other changes in urine composition | TPKVAL 4,43,1962 |
| oral/rat | lethal dose (50 percent kill): 3250 mg/kg | BDERB* 83,157,2008 | |
| oral/rat | lethal dose (50 percent kill): 1200 mg/kg | Reproductive: Effects on fertility: Female fertility index (e.g., # females pregnant per # sperm positive females; # females pregnant per # females mated) | LIFSAK 69,2611,2001 |
| oral/rat | lowest published toxic dose: 1000 mg/kg | Immunological Including Allergic: Decrease in cellular immune response | LIFSAK 69,2611,2001 |
| skin/rabbit | lethal dose (50 percent kill): 3 mL/kg | BDERB* 83,157,2008 | |
| subcutaneous/mouse | lowest published lethal dose: 2500 mg/kg | Behavioral: Somnolence (general depressed activity) Cardiac: Other changes Lung, Thorax, or Respiration: Changes in pulmonary vascular resistance | TPKVAL 2,50,1961 |
| subcutaneous/mouse | lowest published toxic dose: 100 mg/kg | Related to Chronic Data: Changes in uterine weight Biochemical: Metabolism (intermediary): Other proteins | TOLED5 144,257,2003 |
| subcutaneous/mouse | lowest published toxic dose: 100 µg/kg | Reproductive: Maternal effects: Uterus, cervix, vagina | TOXID9 72,134,2003 |
| subcutaneous/mouse | lowest published lethal dose: 2500 mg/kg | Behavioral: Somnolence (general depressed activity) Liver: Fatty liver degeneration Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TPKVAL 2,50,1961 |
| subcutaneous/mouse | lowest published toxic dose: 25 µg/kg | Kidney, Ureter, and Bladder: Urine volume decreased or anuria Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphatases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | FCTOD7 114,270,2018 |
| subcutaneous/rabbit | lethal dose (50 percent kill): 3000 mg/kg | VCVGK* -,234,1994 | |
| subcutaneous/rat | lowest published toxic dose: 5.9 mg/kg | Endocrine: Estrogenic | JAFCAU 18,1108,1970 |
| subcutaneous/rat | lowest published toxic dose: 400 mg/kg | Reproductive: Maternal effects: Uterus, cervix, vagina Biochemical: Metabolism (intermediary): Other proteins | JTEHF8 70,171,2007 |
| subcutaneous/rat | lowest published toxic dose: 50 µg/kg | Brain and Coverings: Other degenerative changes Behavioral: Alteration of classical conditioning | TXAPA9 255,221,2011 |
| subcutaneous/rat | lowest published toxic dose: 500 µg/kg | Brain and Coverings: Other degenerative changes Behavioral: Alteration of classical conditioning Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Phosphokinase | TXAPA9 255,221,2011 |
| Tank with water/other fish | Inhibitor Concentration: 200 µg/L/4D | Reproductive: Effects on newborn: Physical | NRTXDN 57,163,2016 |
| Tank with water/Zebrafish | toxic concentration: 2283.1 µg/L/90H | Behavioral: Alteration of classical conditioning | TOLED5 276,62,2017 |
| Tank with water/Zebrafish | toxic concentration: 1 µg/L/2W | Reproductive: Maternal effects: Oogenesis Reproductive: Maternal effects: Ovaries, fallopian tubes Biochemical: Metabolism (intermediary): Other proteins | FCTOD7 112,19,2018 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.02 mmol/L 144H | Ear: Tumors Blood: Other changes Musculoskeletal: Other changes | REPTED 33,142,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.02 mmol/L 144H | Skin and Appendages: Other glands | REPTED 33,142,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.07 mmol/L 24H | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | REPTED 33,142,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.07 mmol/L 48H | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | REPTED 33,142,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.07 mmol/L 72H | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | REPTED 33,142,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.02 mmol/L 144H | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | REPTED 33,142,2012 |
| Tank with water/Zebrafish | Lowest published lethal concentration: >70 µmol/L/112H | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Other developmental abnormalities | TXCYAC 291,83,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: >30 µmol/L/112H | Reproductive: Specific developmental abnormalities: Craniofacial (including nose and tongue) Reproductive: Other developmental abnormalities | TXCYAC 291,83,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.01 µmol/L/48H | Behavioral: Change in motor activity (specific assay) | TXCYAC 291,83,2012 |
| Tank with water/Zebrafish | lowest published toxic concentration: 0.1 µmol/L/112H | Behavioral: Alteration of classical conditioning | TXCYAC 291,83,2012 |
| unreported route/mouse | lowest published toxic dose: 100 mg/kg | Blood: Changes in spleen Immunological Including Allergic: Decrease in cellular immune response | TOXID9 60,29,2001 |
Other Multiple Dose Data and References
| Route/Organism | Dose | Effect | Reference |
|---|---|---|---|
| inhalation/mouse | lowest published toxic concentration: 200 mg/m3/2H/31D- intermittent | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,234,1994 |
| inhalation/mouse | lowest published toxic concentration: 200 mg/m3/2H/41D- intermittent | Liver: Fatty liver degeneration Kidney, Ureter, and Bladder: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TPKVAL 2,50,1961 |
| inhalation/mouse | lowest published toxic concentration: 200 mg/m3/41D- intermittent | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TPKVAL 2,50,1961 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/137D- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TPKVAL 7,76,1965 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/2H/122D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TPKVAL 4,43,1962 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/2H/22D- intermittent | Peripheral Nerve and Sensation: Recording from peripheral motor nerve | TPKVAL 4,43,1962 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/2H/34D- intermittent | Blood: Other changes Blood: Changes in erythrocyte (RBC) count | TPKVAL 4,43,1962 |
| inhalation/rat | lowest published toxic concentration: 150 mg/m3/6H/13W- intermittent | Olfaction: Other olfaction effects Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOXID9 8,248,1988 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/4H/122D- intermittent | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Nutritional and Gross Metabolic: Weight loss or decreased weight gain | VCVGK* -,234,1994 |
| inhalation/rat | lowest published toxic concentration: 47 mg/m3/2H/19W- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Urine volume decreased or anuria Endocrine: Changes in spleen weight | TPKVAL 4,43,1962 |
| intraperitoneal/mouse | lowest published toxic dose: 140 mg/kg/4W- intermittent | Immunological Including Allergic: Increase in humoral response Biochemical: Metabolism (intermediary): Histamines (including liberation not immunochemical in origin) | FCTOD7 50,2109,2012 |
| intraperitoneal/rat | lowest published toxic dose: 320 mg/kg/4W- continuous | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | FCTOD7 41,1035,2003 |
| oral/domestic bird | lowest published toxic dose: 245 mg/kg/7W- intermittent | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | EESADV 128,61,2016 |
| oral/mammal (species unspecified) | lowest published toxic dose: 700 mg/kg/2W- continuous | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Hepatic microsomal mixed oxidase (dealkylation, hydroxylation, etc.) | JJTHEC 65,933,2002 |
| oral/mammal (species unspecified) | lowest published toxic dose: 3500 mg/kg/2W- continuous | Liver: Changes in liver weight | JJTHEC 65,933,2002 |
| oral/mouse | lowest published toxic dose: 18.3 gm/kg/61D- continuous | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Related to Chronic Data: Changes in testicular weight | FCTOD7 41,1035,2003 |
| oral/mouse | lowest published toxic dose: 1500 mg/kg/3D- intermittent | Related to Chronic Data: Changes in uterine weight | TOXID9 60,297,2001 |
| oral/mouse | lowest published toxic dose: 6300 mg/kg/3W- continuous | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight | TOXID9 66,372,2002 |
| oral/mouse | lowest published toxic dose: 10500 mg/kg/6W- continuous | Reproductive: Maternal effects: Parturition Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in tubules (including acute renal failure, acute tubular necrosis) | TOXID9 66,372,2002 |
| oral/mouse | lowest published toxic dose: 273 gm/kg/13W- continuous | Liver: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-215,1982 |
| oral/mouse | lowest published toxic dose: 12252 mg/kg/14D- continuous | Behavioral: Food intake (animal) | NTIS** #PB86103207 |
| oral/mouse | lowest published toxic dose: 257250 mg/kg/21W- intermittent | Liver: Changes in liver weight | NTIS** #PB86103207 |
| oral/mouse | lowest published toxic dose: 257250 mg/kg/21W- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | NTIS** #PB86103207 |
| oral/mouse | lowest published toxic dose: 257250 mg/kg/21W- continuous | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | NTIS** #PB89169254 |
| oral/mouse | lowest published toxic dose: 2400 mg/kg/15D- intermittent | Reproductive: Paternal effects: Testes, epididymis, sperm duct Reproductive: Other effects on male | TOLED5 199,129,2010 |
| oral/mouse | lowest published toxic dose: 105 mg/kg/5W- intermittent | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | TXAPA9 314,98,2017 |
| oral/mouse | lowest published toxic dose: 750 µg/kg/15D- intermittent | Reproductive: Maternal effects: Oogenesis | TXAPA9 289,507,2015 |
| oral/mouse | lowest published toxic dose: 200 mg/kg/39D- intermittent | Behavioral: Change in psychophysiological tests | TXAPA9 329,75,2017 |
| oral/mouse | lowest published toxic dose: 55 mg/kg/11D- intermittent | Nutritional and Gross Metabolic: Changes in: Ca Kidney, Ureter, and Bladder: Other changes | TXCYAC 303,99,2013 |
| oral/mouse | lowest published toxic dose: 550 mg/kg/11D- intermittent | Gastrointestinal: Other changes | TXCYAC 303,99,2013 |
| oral/mouse | lowest published toxic dose: 1750 mg/kg/35D- continuous | Brain and Coverings: Other degenerative changes Behavioral: Change in psychophysiological tests Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: True cholinesterase | FCTOD7 60,177,2013 |
| oral/mouse | lowest published toxic dose: 280 mg/kg/8W- intermittent | Reproductive: Effects on fertility: Female fertility index (e.g., # females pregnant per # sperm positive females; # females pregnant per # females mated) Reproductive: Effects on fertility: Pre- implantation mortality (e.g., reduction in number of implants per female; total number of implants per corpora lutea) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) | MUREAV 789-790,36,2015 |
| oral/mouse | lowest published toxic dose: 280 mg/kg/8W- intermittent | Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus) | MUREAV 789-790,36,2015 |
| oral/mouse | lowest published toxic dose: 1220 µg/kg/244D- continuous | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Liver: Other changes | TXCYAC 325,133,2014 |
| oral/mouse | lowest published toxic dose: 122 mg/kg/244D- continuous | Endocrine: Hyperglycemia Biochemical: Metabolism (intermediary): Glycolytic Biochemical: Metabolism (intermediary): Lipids including transport | TXCYAC 325,133,2014 |
| oral/mouse | lowest published toxic dose: 4.9 mg/kg/7W- intermittent | Reproductive: Maternal effects: Oogenesis | MUREAV 651,64,2008 |
| oral/mouse | lowest published toxic dose: 140 mg/kg/14D- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases Biochemical: Metabolism (intermediary): Effect on mitochondrial function | FCTOD7 49,2849,2011 |
| oral/mouse | lowest published toxic dose: 14 mg/kg/2W- intermittent | Brain and Coverings: Other degenerative changes | FCTOD7 49,3383,2011 |
| oral/mouse | lowest published toxic dose: 280 mg/kg/2W- intermittent | Brain and Coverings: Other degenerative changes Behavioral: Alteration of classical conditioning | FCTOD7 49,3383,2011 |
| oral/pig | lowest published toxic dose: 1.4 mg/kg/28D- intermittent | Immunological Including Allergic: Increase in cellular immune response Immunological Including Allergic: Decrease in cellular immune response | NRTXDN 66,78,2018 |
| oral/rabbit | lowest published toxic dose: 31500 mg/kg/9W- intermittent | Kidney, Ureter, and Bladder: Other changes in urine composition Blood: Changes in erythrocyte (RBC) count Biochemical: Metabolism (intermediary): Lipids including transport | GISAAA 33(7),25,1968 |
| oral/rabbit | lowest published toxic dose: 4550 mg/kg/26W- intermittent | Kidney, Ureter, and Bladder: Other changes in urine composition Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Endocrine: Other changes | GISAAA 33(7),25,1968 |
| oral/rat | lowest published toxic dose: 42 gm/kg/8W- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | ARZNAD 9,9,1959 |
| oral/rat | lowest published toxic dose: 5460 mg/kg/13W- continuous | Gastrointestinal: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | NTPTR* NTP-TR-215,1982 |
| oral/rat | lowest published toxic dose: 31500 mg/kg/9W- intermittent | Kidney, Ureter, and Bladder: Urine volume increased Liver: Other changes Blood: Other hemolysis with or without anemia | GISAAA 33(7),25,1968 |
| oral/rat | lowest published toxic dose: 455 mg/kg/26W- intermittent | Behavioral: Alteration of classical conditioning Liver: Liver function tests impaired Blood: Other changes | GISAAA 33(7),25,1968 |
| oral/rat | lowest published toxic dose: 4.2 gm/kg/14D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | LIFSAK 69,2611,2001 |
| oral/rat | lowest published toxic dose: 7 mg/kg/7D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | LIFSAK 69,2611,2001 |
| oral/rat | lowest published toxic dose: 1.2 gm/kg/4D- intermittent | Behavioral: Food intake (animal) | LIFSAK 69,2611,2001 |
| oral/rat | lowest published toxic dose: 20 gm/kg/20D- intermittent | Gastrointestinal: Other changes | LIFSAK 69,2611,2001 |
| oral/rat | lowest published toxic dose: 2500 mg/kg/25D- intermittent | Reproductive: Maternal effects: Menstrual cycle changes or disorders | TOSCF2 54,154,2000 |
| oral/rat | lowest published toxic dose: 10.25 gm/kg/22D- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | ARTODN 75,42,2001 |
| oral/rat | lowest published toxic dose: 20.5 gm/kg/44D- continuous | Liver: Changes in liver weight | ARTODN 75,42,2001 |
| oral/rat | lowest published toxic dose: 10.34 gm/kg/44D- continuous | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Other effects on male | ARTODN 75,42,2001 |
| oral/rat | lowest published toxic dose: 41.8 gm/kg/44D- continuous | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands Related to Chronic Data: Changes in prostate weight | ARTODN 75,42,2001 |
| oral/rat | lowest published toxic dose: 600 mg/kg/3D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina Related to Chronic Data: Changes in uterine weight | CRTOEC 14,149,2001 |
| oral/rat | lowest published toxic dose: 10000 mg/kg/10D- intermittent | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | VCVGK* -,234,1994 |
| oral/rat | lowest published toxic dose: 16800 µg/kg/12W- intermittent | Cardiac: Changes in heart weight | REPTED 15,505,2001 |
| oral/rat | lowest published toxic dose: 1.4 µg/kg/1W- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | REPTED 15,505,2001 |
| oral/rat | lowest published toxic dose: 1420 µg/kg/71D- intermittent | Endocrine: Change in LH Endocrine: Evidence of thyroid hypofunction | REPTED 15,505,2001 |
| oral/rat | lowest published toxic dose: 300 mg/kg/3D- intermittent | Reproductive: Maternal effects: Menstrual cycle changes or disorders | TOSCF2 54,154,2000 |
| oral/rat | lowest published toxic dose: 480 mg/kg/3D- intermittent | Endocrine: Estrogenic Related to Chronic Data: Changes in uterine weight | EVHPAZ 108,1147,2000 |
| oral/rat | lowest published toxic dose: 1400 µg/kg/14D- intermittent | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | TOXID9 60,384,2001 |
| oral/rat | lowest published toxic dose: 2772 µg/kg/12W- intermittent | Biochemical: Metabolism (intermediary): Lipids including transport | TXCYAC 213,13,2005 |
| oral/rat | lowest published toxic dose: 6000 mg/kg/12D- intermittent | Liver: Changes in liver weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in prostate weight | TOXID9 60,297,2001 |
| oral/rat | lowest published toxic dose: 600 mg/kg/3D- intermittent | Endocrine: Other changes | ARTODN 80,839,2006 |
| oral/rat | lowest published toxic dose: 200 mg/kg/4D- intermittent | Related to Chronic Data: Changes in uterine weight | REPTED 17,421,2003 |
| oral/rat | lowest published toxic dose: 400 mg/kg/4D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina | REPTED 17,421,2003 |
| oral/rat | lowest published toxic dose: 31080 µg/kg/12W- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina | TXCYAC 205,103,2004 |
| oral/rat | lowest published toxic dose: 2700 mg/kg/18D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | ARTODN 78,97,2004 |
| oral/rat | lowest published toxic dose: 16800 mg/kg/28D- intermittent | Cardiac: Changes in heart weight Endocrine: Differential effect of sex or castration on observed toxicity Nutritional and Gross Metabolic: Weight loss or decreased weight gain | ARTODN 76,65,2002 |
| oral/rat | lowest published toxic dose: 7000 mg/kg/1W- intermittent | Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field Endocrine: Differential effect of sex or castration on observed toxicity | ARTODN 76,65,2002 |
| oral/rat | lowest published toxic dose: 3500 µg/kg/14D- intermittent | Behavioral: Alteration of classical conditioning | TOXID9 1,113,2001 |
| oral/rat | lowest published toxic dose: 15 mg/kg/3D- intermittent | Related to Chronic Data: Changes in uterine weight | TOXID9 60,296,2001 |
| oral/rat | lowest published toxic dose: 6 µg/kg/30D- intermittent | Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects | TXCYAC 188,117,2003 |
| oral/rat | lowest published toxic dose: 5040 mg/kg/6W- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOXID9 72,84,2003 |
| oral/rat | lowest published toxic dose: 3000 mg/kg/30D- intermittent | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in both tubules and glomeruli Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) | TOLED5 143,261,2003 |
| oral/rat | lowest published toxic dose: 1320 mg/kg/33D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | ETOPFR 14,99,2003 |
| oral/rat | lowest published toxic dose: 13200 mg/kg/33D- intermittent | Endocrine: Changes in thymus weight | ETOPFR 14,99,2003 |
| oral/rat | lowest published toxic dose: 700 mg/kg/14D- intermittent | Endocrine: Change in LH Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TOLED5 211,201,2012 |
| oral/rat | lowest published toxic dose: 2800 mg/kg/14D- intermittent | Reproductive: Paternal effects: Testes, epididymis, sperm duct Biochemical: Metabolism (intermediary): Other | TOLED5 211,201,2012 |
| oral/rat | lowest published toxic dose: 600 mg/kg/30D- intermittent | Cardiac: Other changes | TOLED5 250-251,1,2016 |
| oral/rat | lowest published toxic dose: 15 mg/kg/30D- intermittent | Behavioral: Fluid intake Liver: Hepatitis (hepatocellular necrosis), zonal Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) | FCTOD7 107,395,2017 |
| oral/rat | lowest published toxic dose: 535.714 mg/kg/50D- intermittent | Brain and Coverings: Other degenerative changes Kidney, Ureter, and Bladder: Changes in both tubules and glomeruli Kidney, Ureter, and Bladder: Changes in kidney weight | TOXRE* 1,92,2014 |
| oral/rat | lowest published toxic dose: 535.714 mg/kg/50D- intermittent | Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Reproductive: Paternal effects: Testes, epididymis, sperm duct Biochemical: Metabolism (intermediary): Lipids including transport | TOXRE* 1,92,2014 |
| oral/rat | lowest published toxic dose: 45 mg/kg/90D- intermittent | Liver: Other changes | FCTOD7 111,125,2018 |
| oral/rat | lowest published toxic dose: 15 mg/kg/30D- intermittent | Liver: Other changes Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other proteins | FCTOD7 112,26,2018 |
| oral/rat | lowest published toxic dose: 400 µg/kg/20D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Endocrine: Evidence of thyroid hypofunction | FCTOD7 95,168,2016 |
| oral/rat | lowest published toxic dose: 8400 mg/kg/6W- intermittent | Endocrine: Change in LH Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | JOETD7 193,321,2016 |
| oral/rat | lowest published toxic dose: 200 mg/kg/40D- intermittent | TXCYAC 329,1,2015 | |
| oral/rat | lowest published toxic dose: 7350 µg/kg/21W- intermittent | TXCYAC 329,21,2015 | |
| oral/rat | lowest published toxic dose: 15400 µg/kg/44W- intermittent | TXCYAC 329,21,2015 | |
| oral/rat | lowest published toxic dose: 0.175 mg/kg/10W- continuous | Liver: Other changes | TXCYAC 303,125,2013 |
| oral/rat | lowest published toxic dose: 1.75 mg/kg/10W- continuous | Liver: Fatty liver degeneration Biochemical: Metabolism (intermediary): Lipids including transport | TXCYAC 303,125,2013 |
| oral/rat | lowest published toxic dose: 3500 mg/kg/70D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | REPTED 28,196,2009 |
| oral/rat | lowest published toxic dose: 0.225 µg/kg/45D- intermittent | Endocrine: Other changes Reproductive: Paternal effects: Testes, epididymis, sperm duct Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases | FCTOD7 50,1124,2012 |
| oral/rat | lowest published toxic dose: 550 mg/kg/50D- intermittent | Liver: Hepatitis (hepatocellular necrosis), zonal Blood: Changes in leukocyte (WBC) count Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Transaminases | FCTOD7 48,2865,2010 |
| oral/rat | lowest published toxic dose: 40 µg/kg/20D- intermittent | Behavioral: Alteration of classical conditioning | FCTOD7 49,1404,2011 |
| oral/rat | lowest published toxic dose: 56 µg/kg/28D- intermittent | Brain and Coverings: Other degenerative changes Behavioral: Alteration of classical conditioning Biochemical: Metabolism (intermediary): Lipids including transport | FCTOD7 49,1404,2011 |
| oral/rat | lowest published toxic dose: 180 mg/kg/24W- intermittent | Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other proteins Nutritional and Gross Metabolic: Changes in: Fe | TXCYAC 256,7,2009 |
| oral/rat | lowest published toxic dose: 36050 mg/kg/103W- intermittent | Behavioral: Food intake (animal) Nutritional and Gross Metabolic: Weight loss or decreased weight gain | HPV060 -,-,2006 |
| oral/rat | lowest published toxic dose: 16800 mg/kg/28D- intermittent | Endocrine: Changes in adrenal weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in testicular weight | BDERB* 83,157,2008 |
| oral/rat | lowest published toxic dose: 0.28 mg/kg/7D- intermittent | Behavioral: Change in psychophysiological tests | BDERB* 83,157,2008 |
| oral/rat | lowest published toxic dose: 612 mg/kg/17D- intermittent | Brain and Coverings: Other degenerative changes Behavioral: Change in motor activity (specific assay) Biochemical: Neurotransmitters or modulators (putative): Dopamine at other sites | TOLED5 173,66,2007 |
| oral/rat | lowest published toxic dose: 21 mg/kg/7D- intermittent | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands | NSAPCC 369(Suppl 1),R116,2004 |
| oral/rat | lowest published toxic dose: 1400 µg/kg/14D- intermittent | Behavioral: Alteration of classical conditioning Endocrine: Differential effect of sex or castration on observed toxicity | JTEHF8 66,2077,2003 |
| oral/rat | lowest published toxic dose: 525 mg/kg/45D- intermittent | Brain and Coverings: Other degenerative changes | TXCYAC 249,35,2008 |
| oral/rat | lowest published toxic dose: 6000 mg/kg/6D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | TPKVAL 2,50,1961 |
| oral/rat | lowest published toxic dose: 9000 mg/kg/9D- intermittent | Liver: Other changes Kidney, Ureter, and Bladder: Other changes Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field | TPKVAL 2,50,1961 |
| oral/rat | lowest published toxic dose: 320 µg/kg/8D- intermittent | Brain and Coverings: Other degenerative changes | NETEEC 29,108,2007 |
| subcutaneous/mouse | lowest published toxic dose: 600 mg/kg/2D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina | REPTED 26,94,2008 |
| subcutaneous/mouse | lowest published toxic dose: 300 mg/kg/2W- intermittent | Endocrine: Estrogenic | FCTOD7 109,284,2017 |
| subcutaneous/mouse | lowest published toxic dose: 0.3 mg/kg/3D- continuous | Endocrine: Estrogenic | EVHPAZ 109,55,2001 |
| subcutaneous/mouse | lowest published toxic dose: 300 mg/kg/3D- continuous | Endocrine: Estrogenic Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in uterine weight | EVHPAZ 109,55,2001 |
| subcutaneous/mouse | lowest published toxic dose: 25 mg/kg/5D- intermittent | Endocrine: Changes in spleen weight Immunological Including Allergic: Decrease in cellular immune response | TOLED5 136,217,2003 |
| subcutaneous/rat | lowest published toxic dose: 300 mg/kg/3D- intermittent | Related to Chronic Data: Changes in uterine weight | TXCYAC 207,215,2005 |
| subcutaneous/rat | lowest published toxic dose: 873 mg/kg/9D- intermittent | Reproductive: Effects on fertility: Male fertility index (e.g., # males impregnating females per # males exposed to fertile nonpregnant females) | REPTED 22,20,2006 |
| subcutaneous/rat | lowest published toxic dose: 18 µg/kg/9D- intermittent | Endocrine: Estrogenic Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct | REPTED 22,20,2006 |
| subcutaneous/rat | lowest published toxic dose: 0.004 mg/kg/2D- intermittent | Brain and Coverings: Other degenerative changes Endocrine: Differential effect of sex or castration on observed toxicity | NETEEC 28,111,2006 |
| subcutaneous/rat | lowest published toxic dose: 1800 mg/kg/3D- continuous | Related to Chronic Data: Changes in uterine weight | FCTOD7 41,1517,2003 |
| subcutaneous/rat | lowest published toxic dose: 60 mg/kg/3D- intermittent | Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases | CMSHAF 50,1167,2003 |
| subcutaneous/rat | lowest published toxic dose: 3200 mg/kg/4W- continuous | Liver: Changes in liver weight Kidney, Ureter, and Bladder: Changes in kidney weight Nutritional and Gross Metabolic: Weight loss or decreased weight gain | FCTOD7 41,1035,2003 |
| subcutaneous/rat | lowest published toxic dose: 1000 mg/kg/10D- intermittent | Reproductive: Maternal effects: Menstrual cycle changes or disorders Reproductive: Effects on newborn: Physical | REPTED 17,283,2003 |
| subcutaneous/rat | lowest published toxic dose: 1000 mg/kg/10D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina | REPTED 17,283,2003 |
| subcutaneous/rat | lowest published toxic dose: 4000 mg/kg/10D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in ovarian weight Related to Chronic Data: Changes in uterine weight | REPTED 17,283,2003 |
| subcutaneous/rat | lowest published toxic dose: 150 mg/kg/3D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina Related to Chronic Data: Changes in uterine weight | JTSCDR 26,111,2001 |
| subcutaneous/rat | lowest published toxic dose: 273 mg/kg/15D- continuous | Nutritional and Gross Metabolic: Weight loss or decreased weight gain | CMSHAF 42,917,2001 |
| subcutaneous/rat | lowest published toxic dose: 2400 mg/kg/3D- intermittent | Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in uterine weight | CRTOEC 14,149,2001 |
| subcutaneous/rat | lowest published toxic dose: 30 mg/kg/3D- intermittent | Reproductive: Maternal effects: Uterus, cervix, vagina | CRTOEC 14,149,2001 |
| subcutaneous/rat | lowest published toxic dose: 24 mg/kg/3D- intermittent | Endocrine: Estrogenic Related to Chronic Data: Changes in uterine weight | EVHPAZ 108,1147,2000 |
| subcutaneous/rat | lowest published toxic dose: 1.1 mg/kg/11D- continuous | Endocrine: Estrogenic Skin and Appendages: Other: Breast Tumorigenic: Cells (cultured) transformed | JSBBEZ 60,153,1997 |
| subcutaneous/rat | lowest published toxic dose: 0.1 mg/kg/11D- continuous | Reproductive: Maternal effects: Breasts, lactation (prior to or during pregnancy) | JSTBBK 60,153,1997 |
| subcutaneous/rat | lowest published toxic dose: 150 µg/kg/3D- intermittent | Brain and Coverings: Other degenerative changes | NRTXDN 33,23,2012 |
| subcutaneous/rat | lowest published toxic dose: 25 mg/kg/10D- intermittent | Endocrine: Change in GH Biochemical: Metabolism (intermediary): Other | TOLED5 213,325,2012 |
| subcutaneous/rat | lowest published toxic dose: 20000 µg/kg/2D- intermittent | Brain and Coverings: Other degenerative changes | NRTXDN 28,1,2007 |
| subcutaneous/rat | lowest published toxic dose: 30 µg/kg/5D- intermittent | Reproductive: Paternal effects: Prostate, seminal vesicle, Cowper's gland, accessory glands Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other hydrolases Related to Chronic Data: Changes in prostate weight | CNREA8 66,5624,2006 |
| subcutaneous/rat | lowest published toxic dose: 500 µg/kg/5D- intermittent | Endocrine: Changes in pituitary weight Reproductive: Effects on newborn: Physical | JTPAE7 18,203,2005 |
| subcutaneous/rat | lowest published toxic dose: 50 µg/kg/5D- intermittent | Endocrine: Changes in pituitary weight | JTPAE7 18,203,2005 |
| subcutaneous/rat | lowest published toxic dose: 5000 µg/kg/5D- intermittent | Related to Chronic Data: Changes in prostate weight | JTPAE7 18,203,2005 |
| subcutaneous/rat | lowest published toxic dose: 2000 µg/kg/5D- intermittent | Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Reproductive: Paternal effects: Testes, epididymis, sperm duct Biochemical: Metabolism (intermediary): Other proteins | TXCYAC 265,56,2009 |
| subcutaneous/rat | lowest published toxic dose: 2400 mg/kg/6W- intermittent | Endocrine: Estrogenic Nutritional and Gross Metabolic: Weight loss or decreased weight gain Related to Chronic Data: Changes in prostate weight | TOLED5 194,16,2010 |
| subcutaneous/rat | lowest published toxic dose: 4800 mg/kg/6W- intermittent | Endocrine: Change in LH Biochemical: Metabolism (intermediary): Other Related to Chronic Data: Changes in testicular weight | TOLED5 194,16,2010 |
| subcutaneous/rat | lowest published toxic dose: 12 µg/kg/5D- intermittent | Reproductive: Paternal effects: Testes, epididymis, sperm duct | TOXID9 -,280,2009 |
| subcutaneous/rat | lowest published toxic dose: 200 mg/kg/4D- intermittent | Brain and Coverings: Other degenerative changes Endocrine: Other changes | NRTXDN 30,350,2009 |
| subcutaneous/rat | lowest published toxic dose: 200 mg/kg/4D- intermittent | Brain and Coverings: Other degenerative changes Nutritional and Gross Metabolic: Other changes | NRTXDN 32,38,2011 |
| subcutaneous/rat | lowest published toxic dose: 200 µg/kg/4D- intermittent | Brain and Coverings: Other degenerative changes | NRTXDN 32,38,2011 |
Reviews
| Organization | Standard | Reference |
|---|---|---|
| TOXICOLOGY REVIEW | FAATDF 13,747,1989 | |
| TOXICOLOGY REVIEW | FCTOD7 40,905,2002 | |
| TOXICOLOGY REVIEW | TOLED5 127,225,2002 | |
| TOXICOLOGY REVIEW | TOLED5 131,75,2002 | |
| TOXICOLOGY REVIEW | MUREAV 543,201,2003 | |
| TOXICOLOGY REVIEW | TOLED5 140-141,37,2003 | |
| TOXICOLOGY REVIEW | MUTAEX 14,5,1999 | |
| TOXICOLOGY REVIEW | EMMUEG 43,36,2004 | |
| TOXICOLOGY REVIEW | REPTED 20,441,2005 | |
| TOXICOLOGY REVIEW | REPTED 22,164,2006 | |
| TOXICOLOGY REVIEW | MUREAV 613,68,2006 | |
| TOXICOLOGY REVIEW | ENTOX* -,314,2005 | |
| TOXICOLOGY REVIEW | ENTOX* -,258,2005 | |
| TOXICOLOGY REVIEW | MUREAV 584,1,2005 | |
| TOXICOLOGY REVIEW | MUREAV 651,1,2008 | |
| TOXICOLOGY REVIEW | JTEHD6 7,1,2004 | |
| TOXICOLOGY REVIEW | REPTED 25,192,2008 | |
| TOXICOLOGY REVIEW | REPTED 23,337,2007 | |
| TOXICOLOGY REVIEW | REPTED 23,374,2007 | |
| TOXICOLOGY REVIEW | REPTED 23,297,2007 | |
| TOXICOLOGY REVIEW | MUTAEX 19,423,2004 | |
| TOXICOLOGY REVIEW | JTPAE7 17,69,2004 | |
| TOXICOLOGY REVIEW | MUREAV 672,10,2009 | |
| TOXICOLOGY REVIEW | MUREAV 672,17,2009 | |
| TOXICOLOGY REVIEW | HTOPA* 1,501,2002 | |
| TOXICOLOGY REVIEW | FCTOD7 46,2307,2008 | |
| TOXICOLOGY REVIEW | TPHSDY 29,116,2008 | |
| TOXICOLOGY REVIEW | JTSCDR 33,389,2008 | |
| TOXICOLOGY REVIEW | FCTOD7 47,1287,2009 | |
| TOXICOLOGY REVIEW | MUREAV 678,113,2009 | |
| TOXICOLOGY REVIEW | FESTAS 90,911,2008 | |
| TOXICOLOGY REVIEW | ARTODN 83,281,2009 | |
| TOXICOLOGY REVIEW | REPTED 31,337,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,205,2011 | |
| TOXICOLOGY REVIEW | MUTAEX 26,199,2011 | |
| TOXICOLOGY REVIEW | NRTXDN 31,589,2010 | |
| TOXICOLOGY REVIEW | MUREAV 714,105,2011 | |
| TOXICOLOGY REVIEW | REPTED 31,272,2011 | |
| TOXICOLOGY REVIEW | REPTED 33,269,2012 | |
| TOXICOLOGY REVIEW | FCTOD7 49,1877,2011 | |
| TOXICOLOGY REVIEW | REPTED 38,1,2013 | |
| TOXICOLOGY REVIEW | REPTED 34,298,2012 | |
| TOXICOLOGY REVIEW | MUREAV 746,113,2012 | |
| TOXICOLOGY REVIEW | TXAPA9 254,86,2011 | |
| TOXICOLOGY REVIEW | EMMUEG 55,278,2014 | |
| TOXICOLOGY REVIEW | EMMUEG 55,155,2014 | |
| TOXICOLOGY REVIEW | MUREAV 764-765,46,2014 | |
| TOXICOLOGY REVIEW | EMMUEG 49,4,2008 | |
| TOXICOLOGY REVIEW | MUREAV 764-765,36,2014 | |
| TOXICOLOGY REVIEW | TOLED5 201,152,2011 | |
| TOXICOLOGY REVIEW | TOLED5 202,36,2011 | |
| TOXICOLOGY REVIEW | TOLED5 204,190,2011 | |
| TOXICOLOGY REVIEW | REPTED 49,117,2014 | |
| TOXICOLOGY REVIEW | MUREAV 763,181,2015 | |
| TOXICOLOGY REVIEW | TOLED5 210,141,2012 | |
| TOXICOLOGY REVIEW | MUREAV 733,21,2012 | |
| TOXICOLOGY REVIEW | TXCYAC 307,35,2013 | |
| TOXICOLOGY REVIEW | TXCYAC 307,66,2013 | |
| TOXICOLOGY REVIEW | TXCYAC 311,13,2013 | |
| TOXICOLOGY REVIEW | TXCYAC 311,41,2013 | |
| TOXICOLOGY REVIEW | TXAPA9 261,227,2012 | |
| TOXICOLOGY REVIEW | REPTED 58,33,2015 | |
| TOXICOLOGY REVIEW | MUREAV 767,67,2016 | |
| TOXICOLOGY REVIEW | NETEEC 36,17,2013 | |
| TOXICOLOGY REVIEW | FCTOD7 86,298,2015 | |
| TOXICOLOGY REVIEW | TXCYAC 313,3,2013 | |
| TOXICOLOGY REVIEW | TXCYAC 325,74,2014 | |
| TOXICOLOGY REVIEW | FCTOD7 92,58,2016 | |
| TOXICOLOGY REVIEW | MUREAV 802,1,2016 | |
| TOXICOLOGY REVIEW | NETEEC 52,25,2015 | |
| TOXICOLOGY REVIEW | NETEEC 52,88,2015 | |
| TOXICOLOGY REVIEW | REPTED 69,174,2017 | |
| TOXICOLOGY REVIEW | NRTXDN 55,92,2016 | |
| TOXICOLOGY REVIEW | REPTED 65,224,2016 | |
| TOXICOLOGY REVIEW | REPTED 59,167,2016 | |
| TOXICOLOGY REVIEW | REPTED 54,58,2015 | |
| TOXICOLOGY REVIEW | REPTED 54,141,2015 | |
| TOXICOLOGY REVIEW | REPTED 54,148,2015 | |
| TOXICOLOGY REVIEW | REPTED 71,71,2017 | |
| TOXICOLOGY REVIEW | EMMUEG 56,637,2015 | |
| TOXICOLOGY REVIEW | EMMUEG 57,579,2016 | |
| TOXICOLOGY REVIEW | FCTOD7 105,429,2017 | |
| TOXICOLOGY REVIEW | FCTOD7 109,1,2017 | |
| TOXICOLOGY REVIEW | TOLED5 254,52,2016 | |
| TOXICOLOGY REVIEW | TOLED5 265,106,2017 | |
| TOXICOLOGY REVIEW | ETOPFR 47,182,2016 | |
| TOXICOLOGY REVIEW | FCTOD7 109,812,2017 | |
| TOXICOLOGY REVIEW | REPTED 79,21,2018 | |
| TOXICOLOGY REVIEW | REPTED 81,140,2018 | |
| TOXICOLOGY REVIEW | RTOPDW 55,43,2009 | |
| TOXICOLOGY REVIEW | REPTED 81,147,2018 | |
| TOXICOLOGY REVIEW | REPTED 57,59,2015 | |
| TOXICOLOGY REVIEW | REPTED 79,96,2018 | |
| TOXICOLOGY REVIEW | RTOPDW 60,120,2011 | |
| TOXICOLOGY REVIEW | RTOPDW 61,251,2011 | |
| TOXICOLOGY REVIEW | SFDRA* 38,523,2016 | |
| TOXICOLOGY REVIEW | VETOX* ,805,2018 |
Standards and Regulations
| Organization | Standard | Reference |
|---|---|---|
| Occupational Exposure Limit-AUSTRIA | MAK-TMW 5 mg/m3);KZW 5 mg/m3, inhal, sen, 2007 | |
| Occupational Exposure Limit-GERMANY | MAK 5 mg/m3, inhal, 2011 | |
| Occupational Exposure Limit-RUSSIA | short term exposure limit 5 mg/m3, JUN2003 | |
| Occupational Exposure Limit-SWITZERLAND | ceiling concentration 5 mg/m3, inhal, sen, JAN2011 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 5 mg/m3 (respirable dust), 2003 | |
| Occupational Exposure Limit-THE NETHERLANDS | MAC-TGG 10 mg/m3 (total dust), 2003 | |
| Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) | ceiling concentration 0.5 ppm (2.8 mg/m3) | CFRGBR 29,1915.1000,1993 |
NIOSH Documentation and Surveillance
Status in Federal Agencies
Page last reviewed: November 16, 2018
Content
source: National Institute for Occupational Safety and Health